©2024 Stanford Medicine
Inhaled PGE1 in Neonatal Hypoxemic Respiratory Failure
Not Recruiting
Trial ID: NCT00598429
Purpose
This pilot study was a randomized, placebo-controlled, clinical trial to test the safety of
using the intravenous form of Prostaglandin E1 (PGE1) in an inhaled form for treatment of
hypoxemic respiratory failure in term newborns. The study planned to enroll 50 infants
diagnosed with hypoxemic respiratory failure at nine NICHD Neonatal Research Network sites,
and randomly assign them to receive one dose over a 72-hour period of either high
concentration PGE1 (300 ng/kg/min), low concentration PGE1 (150 ng/kg/min), or placebo
(normal saline, the diluent for the drug). In addition to determining the safety, optimal
dose, and duration of the therapy, this pilot trial planned to evaluate the feasibility of
conducting a larger, multi-center randomized, blinded placebo-controlled trial.
Official Title
Randomized Clinical Trial of Inhaled PGE1 (IPGE1) in Neonatal Hypoxemic Respiratory Failure. A Protocol for the NICHD Neonatal Research Network
Stanford Investigator(s)
Eligibility
Inclusion Criteria:
- Infants born at 34 0/7ths weeks gestational age or greater (by best obstetrical
estimate) and at a postnatal age no greater than 7 days (168 hours)
- Infants diagnosed with hypoxemic respiratory failure (HRF), including perinatal
aspiration syndrome (meconium, blood, or amniotic fluid), pneumonia/ sepsis,
respiratory distress syndrome, or idiopathic respiratory failure
- Infants who will receive assisted ventilation for HRF
- Infants with an oxygenation index (MAP x FiO2 x 100/PaO2)(OI) of 15-25 on two arterial
gases taken between 15 minutes and 12 hours apart
- An indwelling arterial line
- Infants whose parents/legal guardians have provided consent for enrollment
Exclusion Criteria:
- Any infant in whom a decision has been made not to provide full treatment
- Known structural congenital heart disease, except patent ductus arteriosus and
atrial/ventricular level shunts
- Congenital diaphragmatic hernia
- Preterm neonates less than 34 weeks
- Thrombocytopenia (platelet count < 80,000/μl) unresponsive to platelet transfusion
- Infants receiving hypothermia for hypoxic ischemic encephalopathy
- Previous treatment with inhaled nitric oxide
- Infants already enrolled in a conflicting and/or Investigational New Drug (IND)
clinical trial
- Infants whose parents/legal guardians refuse consent
Intervention(s):
drug: inhaled Prostaglandin E1
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Bethany Ball
6507258342